Selina Gierer, DO
Allergy & Immunology · Kansas City, KSNPI 1639399108
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $9,456 of the $12,851 with a category attached, or 73.6%. 22 manufacturers reported payments, led by Sanofi at 38.7% of the total. Reporting peaked in 2024 at $6,466 and has fallen 84.7% since, to $988 in 2025.
Across 107 payments — averaging $120.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$5K
- AstraZeneca$4K
- Blueprint Medicines Corporation$2K
- Genentech USA, Inc.$372
- Regeneron Healthcare Solutions, Inc.$238
- Biocryst US Sales Co., LLC$181
- plus $1K from 16 others
Across 136 payments — averaging $3101.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Shire North American Group Inc$117K
- GSK$102K
- Roche Products Limited$65K
- Ionis Pharmaceuticals, Inc.$61K
- Takeda Pharmaceuticals U.S.A., Inc.$42K
- AstraZeneca$35K
What the payments were for
- Consulting fees$9,45674%
- Food & beverage$3,21525%
- Education$1801%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 17 | $4,974 |
| AstraZeneca | 18 | $3,647 |
| Blueprint Medicines Corporation | 4 | $2,277 |
| Genentech USA, Inc. | 17 | $372 |
| Regeneron Healthcare Solutions, Inc. | 4 | $238 |
| Biocryst US Sales Co., LLC | 4 | $181 |
| Amgen | 5 | $174 |
| GSK | 5 | $149 |
| Novartis | 5 | $136 |
| Incyte Corporation | 2 | $136 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Bio Products Laboratory USA, Inc. | 7 | $81 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $68 |
| Pharming Healthcare, Inc. | 2 | $67 |
| Kedrion Biopharma, Inc. | 3 | $53 |
| CSL Behring | 2 | $52 |
| Hospira, Inc. | 2 | $41 |
| Grifols USA, LLC | 2 | $38 |
| GC Biopharma USA, Inc. | 1 | $23 |
| Lilly USA, LLC | 1 | $18 |
| Corcept Therapeutics | 1 | $14 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,851 in reported general payments places this provider in the 75th percentile of 33 allergy & immunology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ActimmuneInterferon Gamma-1b,recomb. | 11 | $913,544 |
| Dupixent PenDupilumab | 109 | $397,236 |
| Dupixent SyringeDupilumab | 51 | $233,449 |
| XolairOmalizumab | 31 | $132,594 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 37 | $122,353 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $16,513 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $12,019 |
| SymbicortBudesonide/Formoterol Fumarate | 33 | $8,855 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $6,945 |
| QnaslBeclomethasone Dipropionate | 21 | $6,429 |
| Epinephrine | 35 | $6,099 |
| Arnuity ElliptaFluticasone Furoate | 19 | $4,421 |
| Qvar RedihalerBeclomethasone Dipropionate | 16 | $4,136 |
| Azelastine Hcl | 81 | $3,560 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $2,436 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenActimmune | $174 | $913,54411 claims |
| Grifols USA, LLCGamunex-C | $38 | $122,35337 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $149 | $27,87953 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $3,647 | $20,87448 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 33 allergy & immunology providers in Kansas.
Other allergy & immunology in Kansas City
- Marissa LoveKansas City$4K
- Damandeep WaliaKansas City$3K
- Hanh HoKansas City$2K
- Jeehyun RhaKansas City$1K
- Timothy NguyenKansas City$743
- Tomara SpiessKansas City$455
- Andrea D'melloKansas City$371
- John MartinezKansas City$76
- Henry KanarekOverland Park$143K
- Celina BernabeOverland Park$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.